Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg

Rendl, Gundula; Rodrigues, Margarida; Schweighofer-Zwink, Gregor; Hutter, Josef; Hittmair, A; Zellinger, Barbara; Hauser‐Kronberger, Cornelia; Pirich, Christian

doi:10.1007/s00508-017-1207-x

Cited by 5 publications

(10 citation statements)

References 25 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were encountered in an Austrian study (54% of TC were pT1). 13 The rate of lymph node metastasis in our study (20.3% of our cases) was lower than the studies conducted by Shah et al 15 (44.7%) and Xiang et al 12 (52.6% TC). This could be explained by the fact that, in our study, there was no data on lymph node status in our Perithyroid involvement was found in 10.7% of our cases and in 6.8%-15.6% of cases in the literature.…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Epidemiological and histopathological characteristics of thyroid carcinoma in a Tunisian health care center

Ben Thayer,

Khanchel,

Helal

et al. 2023

World j. otorhinolaryngol.-head neck surg.

View full text Add to dashboard Cite

BackgroundThyroid carcinoma (TC) accounts for almost 0.5%–1% of total malignancies. Its incidence is increasing rapidly worldwide. Several studies have drawn up the epidemiological profile of TC and its clinical and pathological features. However, to date, no similar studies have been conducted in Tunisia.AimsTo establish an epidemiological profile of TC in a Tunisian health care institute and to analyze its clinical and histopathological characteristics in our institute.Materials and MethodsWe present a retrospective study reviewing the cases of TC diagnosed in our institution in a 4‐year period.ResultsWe collected a sample of 192 cases of TC. It consisted of 31 males and 161 females (83.8%) with a sex‐ratio M/F of 0.19. The mean age was 46.4 years. Papillary thyroid carcinoma was the most frequent histological subtype. The multifocality rate was 33.8%. The mean size of TC was 2.2 ± 1.9 cm. 60.9% of TC were staged pT1 and 20.3% had nodal involvement. Papillary thyroid microcarcinomas were noted in 37.5% of cases.ConclusionOur results were consistent with those of the literature. A high proportion of pT1 and pN0 tumors were noted in our series, suggesting that TC's diagnosis and management was performed at an early stage of the disease in our institution. In addition, our study enabled us to notice the impact of the Coronavirus disease 19 crisis on the management of TC in our institution. Further studies are needed to establish the epidemiological profile of TC in Tunisia and to assess its clinical and pathological features.

show abstract

Section: Discussioncontrasting

confidence: 72%

“…Perithyroid involvement was found in 10.7% of our cases and in 6.8%–15.6% of cases in the literature 12,13,20 …”

Section: Discussionmentioning

confidence: 47%

Epidemiological and histopathological characteristics of thyroid carcinoma in a Tunisian health care center

Ben Thayer,

Khanchel,

Helal

et al. 2023

World j. otorhinolaryngol.-head neck surg.

View full text Add to dashboard Cite

show abstract

“…DTC represents the vast majority of thyroid cancer cases (>90%), including both papillary and follicular forms [3,4]. In 2013, the percentage of the papillary form amounted to 84% among newly diagnosed TC within the federal state of Salzburg, Austria [5].…”

Section: Introductionmentioning

confidence: 99%

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Rendl

Sipos

Becherer

et al. 2020

International Journal of Endocrinology

View full text Add to dashboard Cite

Background. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (PFS) and tolerability in the Austrian patient population treated with lenvatinib. Methods. Clinical data of 43 patients (25 males and 18 females) with a median age of 70 years (range: 39–91 years) and RAI-refractory TC with metastases to the lymph nodes (74%), lungs (86%), bone (35%), liver (16%), and brain (12%) were analyzed. The mean duration of treatment with lenvatinib was 26.6 ± 15.4 months with dosage reductions required in 39 patients (91%). Results. PFS after 24 months was 71% (95% CI: 56–87), and overall survival (OS) was 74% (95% CI: 60–88), respectively. OS was significantly shorter ( p = 0.048 ) in patients with a daily maintenance dosage ≤ 10 mg (63%) (95% CI: 39–86) as compared to patients on ≥ 14 mg lenvatinib (82%) (95% CI: 66–98) daily. Dose reduction was noted in 39 patients (91%). Grade ≥3 toxicities (hypertension, diarrhea, weight loss, and palmar-plantar erythrodysesthesia syndrome) were most common leading to discontinuation of lenvatinib in 7 patients (16%). Conclusion. Lenvatinib showed sustained clinical efficacy in patients with metastatic RAI-refractory TC even with reduced maintenance dosages over years. The effects were comparable to the registration trial, although patients had a higher median age and, more commonly, dose reductions.

show abstract

“…Just four patients with T2 underwent F-18 FDG PET/CT imaging. Thus, study results do not relate to the majority of patients compromising of T1 and T2 tumors [33]. Another limitation of this study is that not all F-18 FDG PET positive lesions could be histologically confirmed.…”

Section: Patmentioning

confidence: 78%

Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

The aim of the study was to evaluate the clinical impact of pre-ablation rhTSH-stimulated fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT in addition to post-therapeutic whole body radioiodine scanning in patients with intermediate to high risk differentiated thyroid carcinoma (DTC). This was a retrospective single center study including 73 patients with thyroid cancer (44 females, mean age 43.2±16.2 years, 62% papillary, 31% follicular, 7% poorly differentiated). All patients underwent ablative radioiodine treatment (mean activity: 3661±673 MBq I-131) using rhTSH after thyroidectomy and lymph node (LN) dissection (01/2013–10/2016) and TSH-stimulated F-18 FDG PET/CT (4 MBq/kg body weight, low dose CT). Post-treatment I-131 whole body scan (I-131 WBS) was obtained 9 days afterwards in planar technique and in case of equivocal or abnormal findings using SPECT/CT. Thirty-one patients (42%) showed F-18 FDG avid lesions, 14 patients showed more FDG than iodine positive lesions and 5 patients more iodine positive lesions in I-131 WBS, respectively. Fifty-three patients showed identical F-18 FDG PET/CT and I-131 WBS. The initial treatment plan was changed from follow-up to therapy (surgery, systemic therapy using tyrosine-kinase inhibition) in 11 patients (15%) on the basis of F-18 FDG PET/CT imaging. Six of these 11 patients had papillary thyroid cancer. Three patients with histologically proven LN metastases had stimulated thyroglobulin-levels<2.0 ng/ml. Our study demonstrated a clinical benefit of pre-ablation rhTSH-stimulated F-18 FDG PET/CT imaging in about 20% of patients with intermediate to high risk DTC, leading to change in patient management in 15%.

show abstract

Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg

Cited by 5 publications

References 25 publications

Epidemiological and histopathological characteristics of thyroid carcinoma in a Tunisian health care center

Epidemiological and histopathological characteristics of thyroid carcinoma in a Tunisian health care center

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer

Contact Info

Product

Resources

About